San Francisco, 11 April , Injectable Drug Delivery Market Analysis, By
Device Type (Self-injection Devices, Conventional Devices), By Formulation
(Conventional Drug Delivery, Novel Drug Delivery), By Therapeutic Use
(Autoimmune Disorders, Hormonal Disorders, Oncology), By End-user Application
(Hospitals, Homecare Settings, Research Institutes, Clinical Laboratories), By
Region (U.S, Canada, Germany, U.K, China, India, South Africa, Saudi Arabia,
Brazil, Mexico) And Segment Forecasts From 2018 to 2024
The global injectable drug delivery market is expected to reach USD
931.1 billion by 2024, according to a new report by Grand View Research, Inc.
The increase in number of chronic diseases like diabetes and cancer has fueled
the need for injectable drug delivery. Unlike other traditional forms of drug
delivery, injectables allow maximum bioavailability of the pharmaceutical drug
as it bypasses the first pass metabolism. With substantial growth in
technological advancements, the devices being manufactured and marketed are
built so as to cater to the specific needs of the patients.
With the advent of
self-injection devices, injectable drugs can be self administered without the
need of medical assistance. A large number of technology-oriented developments
have taken place in the biologics market, which further increases the
applicability of these injectable devices in the challenging disease areas.
Self-injection devices have allowed patients suffering from diabetes to manage
insulin levels with auto-injectors, pen-injectors, and needle-free injectors;
thus, the homecare segment has been a large grosser in the end-user
application.
The major restraints in this
market are injuries and infections caused by needles, ambiguities related to regulatory
reimbursements, sterility of the injectable drugs, and the preference of other
drug delivery systems that possess less toxicity and are easy to administer.
Despite these restraints, the market potential for injectable drug delivery
products is tremendous with majority of the key players opting to injectables
over other forms of delivery. The injectable drug delivery industry, based on
product type is segmented into two sub-types namely self-injection devices and
conventional injection devices. Further, on the basis of therapeutic use, the
injectable drug delivery industry is segmented into autoimmune disorders,
hormonal disorders, oncology, and others.
The injectable drug delivery
industry by end-user application is categorized into hospitals, homecare
settings, and others including research establishments, diagnostics, and
clinical laboratories.
Access Full Research
Report On Injectable Drug Delivery Market
Analysis:
Further key findings from the study suggest:
·
North America is expected to
lead the market for injectable drug delivery devices with the largest number of
patients suffering from chronic diseases like diabetes and cancer along with
autoimmune disorders. The reason why countries in North America are leading is
due to the technological innovations and advanced research in the area that
enable them to excel at designing new and improved drug delivery products.
·
The Asia Pacific market is set
to lead exceptionally well owing to the partnerships with other well
established global players. This region has also witnessed enormous investments
in research and development; thus, accelerating the growth of the injectables
market in this region.
·
The homecare settings has been
the most profit garnering segment with a large cohort of patients suffering
from chronic diseases and hence the resultant high utility of these devices at
a primary level for better control and management of the disease.
·
Some key market players include
Pfizer, Inc., Schott AG, Becton, Dickinson and Company, Baxter International,
Inc., and ELI Lilly & Co.
Browse More Reports Of This Category By
Grand View Research At: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global injectable drug delivery market on the basis of device type, therapeutic
use, formulation, end-user application, and region:
Injectable Drug Delivery by
Type Outlook (Revenue, USD Million, 2013 - 2024)
·
Devices
o
Self- injection devices
o
Conventional injection devices
·
Formulation
o
Conventional Drug Delivery
o
Novel Drug Delivery
o
Others
Injectable Drug Delivery
Therapeutic Use Outlook (Revenue, USD Million, 2013 - 2024)
·
Autoimmune disorders
·
Hormonal disorders
·
Oncology
·
Others
Injectable Drug Delivery
Devices End-User Application Outlook (Revenue, USD Million, 2013 - 2024)
·
Hospitals
·
Homecare Settings
·
Others
Injectable Drug Delivery
Devices Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-injectable-drug-delivery-market
About Grand View Research
Grand View Research, Inc. is a U.S. based
market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment